| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447289 | European Journal of Cancer | 2011 | 9 Pages |
Abstract
Low DNMT1 expression defines a subgroup of GC patients with better outcomes following platinum/5FU-based neoadjuvant chemotherapy. In vitro data support a functional relationship between DNMT1 and cisplatin sensitivity. Besides its potential use as a predictive biomarker, DNMT1 may represent a promising target for alternative therapeutic strategies for a subset of GC patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kathrin Mutze, Rupert Langer, Felix Schumacher, Karen Becker, Katja Ott, Alexander Novotny, Alexander Hapfelmeier, Heinz Höfler, Gisela Keller,